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Abstract
Psychogenic polydipsia or self-induced water intoxication is a potentially lethal condition seen
in many chronic psychiatric patients. This is a literature review based on therapeutic
significance of Naltrexone in improving compulsive water drinking behavior in chronic
psychiatrically ill patients with psychogenic polydipsia. Naltrexone is an opioid antagonist
approved by FDA for alcohol dependence. Extensive literature search provides a line of evidence
that suggests correlation of opioid receptor with compulsive water ingestion in animals.
However, there is limited data regarding clinical utility of naltrexone in improving psychogenic
polydipsia in human species. This review highlights the necessity for further research and trials
to elucidate the role of naltrexone in human psychogenic drinking behavior.
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Introduction And Background
Psychogenic polydipsia (PP) is a chronic episodic condition in psychiatric patients
characterized by compulsive drinking of large amounts of water resulting in dilutional
hyponatremia and various neurological signs. It is estimated that 15% to 25% of patients with
chronic mental disease have psychogenic polydipsia [1,2,3]. Schizophrenia is the most
commonly associated psychiatric disorder with 80% of cases reported with PP [1,2]. The other
psychiatric disorders linked to PP are anorexia nervosa, psychotic depression, and bipolar
depression [4,5,6].
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Psychogenic polydipsia is a three-phase process. First, polydipsia is accompanied by polyuria,
followed by hyponatremia; finally there are occurrences of neurological signs such as delirium,
ataxia, seizures and coma secondary to ingestion of excessive quantity of water [3].
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Review
Psychogenic polydipsia or self-induced water intoxication is a relatively common condition in
chronic psychiatric patients, occurring from 5 to 10 years after the onset of psychosis. It
presents as a chronic condition in 67% of cases, and episodic in 33% of cases [1]. It is defined by
the consumption of more than 3 liters of fluids per day with excretion of profound amount of
dilute urine. Hyponatremia is observed to co-occur in 30% cases of PP [1,7]. However, only onethird to one-fifth of the patients with PP present with symptomatic hyponatremia. PP in
schizophrenics drastically affects the morbidity, mortality and disease prognosis leading to
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reduction in life expectancy by 13% [1,8]. The exact etiology of PP is idiopathic as multiple
factors may play a role in its pathogenesis.
Multiple analyses have suggested race (male Caucasians), smoking, and chronic schizophrenia
to be the strongest risk factors associated with PP [1,3,9]. Moreover, research studies have
speculated that PP with water intoxication occurs more commonly in patients with negative
symptoms of schizophrenia [1,10]. Similarly, hyponatremia in PP was more often observed in
institutionalized psychiatric patients with greater treatment resistance which can contribute to
cognitive decline and delay in processing information [11,12]. Poirier et al attributed alcohol
addiction as a risk factor for development of water intoxication in PP patients [4,13].
The management of PP has always been a challenge for psychiatrists, as there is no definitive
treatment despite its universal existence in many long-term psychiatric facilities. Over the
years, psychiatrists have implemented techniques such as behavior modification and
psychosocial rehabilitation for effective management. Studies have also hypothesized the
possible role of atypical anti-psychotics such as clozapine, olanzapine, and risperidone in
improving the anxiety related to self-drinking behavior [14,15,16]. However, there are varied
theories regarding their efficacy in improving compulsive drinking, as hyponatremia secondary
to olanzapine can further exacerbate the symptoms of psychosis. Animal studies have also
suggested the involvement of the alpha2- adrenergic system in mediating the excessive
drinking behavior in chronic schizophrenics [17].
Naltrexone, an opiate antagonist, is approved by Food and Drug Administration to treat opioid
use disorder and alcohol use disorder. However, over the years, research and molecular studies
have diversified our knowledge regarding implication of opiate receptors. Based on opiate
receptor and its complex interactions, there could be a possibility where naltrexone can play a
significant role in improving self-drinking behaviors. Our understanding regarding
naltrexone’s clinical significance supports the idea by Snyder in the year 1984, where they
correlated the consequences of polydipsia on opiate receptors like addictive behaviors [18,19].
The stereotypic behaviors in PP patients shared some similarity to behaviors observed in LeschNyan syndrome and mentally challenged patients where they showed diminished symptoms
after treatment with an opiate antagonist. This led Nishikawa et al to speculate the role of
naloxone improving PP in some schizophrenics [19,20].
Multiple animal studies have postulated that blockade of opioid neurotransmission leads to
reduction in body weight and thirst mechanism. Opioid peptides and receptors are highly
condensed in paraventricular and supraoptic hypothalamic nuclei which are believed to be the
site of opioid antagonism in animals [21]. Kurbanovb et al studied the effects of naltrexone on
food intake and body weight in olanzapine treated rats. They observed significant reduction in
food intake and body weight in the combined olanzapine and naltrexone treated group in
contrast to the group that only received naltrexone [22].
In an open design study, naltrexone 50 mg PO/day was added for a period of 6-weeks to the
anti-psychotic regimen of seven inpatient PP hyponatremic patients where they demonstrated
significant reduction in mannerisms and diurnal weight change during their last treatment
period. However, the results of the study were limited due to small sample size and warranted
larger studies to support the hypothesis that behaviors such as compulsive drinking were
mediated by endogenous opiates [19,23]. More recently, a successfully treated case of PP has
been reported where a 47-year old male patient with PP responded well to a combination
therapy of irbesartan 300 mg and naltrexone 50 mg [24].

Conclusions
Psychogenic polydipsia is a common condition observed in various psychiatric facilities. Fluid
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restriction is a successful measure to treat the acute symptoms. However, there is a need for
pharmacological intervention to treat the polydipsic symptoms in the long term. Given the
above-mentioned facts, it is implied that naltrexone can play an pivotal role in treating
psychogenic polydipsia in chronic psychiatric patients. However, more cases should be reported
to elaborate the efficacy of naltrexone as an adjuvant in treating self-drinking behaviors.
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